Dabigatran |
Thrombin inhibitor |
Schulman et al.(1919. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52. http://dx.doi.org/10.1056/NEJMoa0906598 https://doi.org/10.1056/NEJMoa0906598...
)
|
Enoxaparin/dabigatran 150 mg every 12 h |
6 |
Dabigatran (2.4%) vs. warfarin (2.1%) |
MB: dabigatran (1.6%) vs. warfarin (1.9%) |
Dabigatran |
Schulman et al.(4746. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033-69, 3069a-3069k.)
|
Enoxaparin/dabigatran 150 mg every 12 h |
6 |
Dabigatran (2.3%) vs. warfarin (2.2%) |
MB: dabigatran (0.3%) vs. warfarin (0.0%) |
Rivaroxaban |
Factor Xa inhibitor |
EINSTEIN Investigators et al.(2121. EINSTEIN Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510. http://dx.doi.org/10.1056/NEJMoa1007903 https://doi.org/10.1056/NEJMoa1007903...
)
|
Rivaroxaban 15 mg every 12 h for 3 weeks; 20 mg/day |
3, 6, or 12 |
Rivaroxaban (2.1%) vs. warfarin (3.0%) |
MRB: rivaroxaban (8.1%) vs. warfarin (8.1%) |
Rivaroxaban |
EINSTEIN Investigators et al.(2222. EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97. http://dx.doi.org/10.1056/NEJMoa1113572 https://doi.org/10.1056/NEJMoa1113572...
)
|
Rivaroxaban 15 mg every 12 h for 3 weeks; 20 mg/day |
3, 6, or 12 |
Rivaroxaban (2.1%) vs. warfarin (1.8%) |
MRB: rivaroxaban (10.3%) vs. warfarin (11.4%) |
Apixaban |
Factor Xa inhibitor |
Agnelli et al.(2323. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. http://dx.doi.org/10.1056/NEJMoa1302507 https://doi.org/10.1056/NEJMoa1302507...
,2424. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708. http://dx.doi.org/10.1056/NEJMoa1207541 https://doi.org/10.1056/NEJMoa1207541...
)
|
Apixaban 10 mg every 12 h for 7 days; 5 mg every 12 h |
6 |
Apixaban (2.3%) vs. warfarin (2.7%) |
MB: apixaban (0.6%) vs. warfarin (1.8%) |
Edoxaban |
Factor Xa inhibitor |
Hokusai-VTE Investigators et al.(2525. Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-15. http://dx.doi.org/10.1056/NEJMoa1306638 https://doi.org/10.1056/NEJMoa1306638...
)
|
Low-molecular-weight heparin for 5 days; edoxaban 60 mg/day |
3-12 |
Edoxaban (3.2%) vs. warfarin (3.5%) |
MRB: edoxaban (8.5%) vs. warfarin (10.3%) |